In patients with T2D and CKD, finerenone lowers the risk for adverse cardiovascular and kidney events compared with placebo, ...
Three separate papers on the kidney drug finerenone landed in the New England Journal of Medicine, The Lancet, and JAMA on the same day, each reporting that the drug met its primary endpoints. The ...
Working backwards, we hypothesized that we could improve kidney function by treating constipation." To address this issue, the group conducted a multicenter Phase II clinical trial (LUBI-CKD TRIAL) at ...
Lubiprostone preserved renal function in stage IIIb-IV CKD patients over 24 weeks without altering uremic toxin levels, suggesting a novel renoprotective mechanism. The trial demonstrated ...
RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – ...
Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease. WHIPPANY, N.J., June 02, 2026--(BUSINES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results